{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T18:09:07Z","timestamp":1787422147110,"version":"build-2736575974"},"reference-count":20,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>To analyze the quality of life (QoL), work productivity and activity impairment (WPAI) and healthcare resource utilization (HCRU) in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients receiving golimumab under routine clinical settings in Germany.<jats:bold>Materials &amp; methods:<\/jats:bold>Prospective observational study, GO-ART, analyzed changes in WPAI, QoL and HCRU during 24\u00a0months of golimumab therapy.<jats:bold>Results:<\/jats:bold>Seven hundred and forty-eight\u00a0patients (RA\u00a0=\u00a0250, PsA\u00a0=\u00a0249 and\u00a0AS\u00a0=\u00a0249) were enrolled. Substantial improvements in WPAI scores presenteeism, activity impairment and total work productivity impairment and QoL were observed at month three and were maintained through month 24. Fewer patients had disease-related hospitalizations and consulted physician at month 24 than at the baseline.<jats:bold>Conclusion:<\/jats:bold>Golimumab induces sustained improvements in WPAI and QoL and reduces healthcare resource utilization in RA, PsA and AS.<\/jats:p>","DOI":"10.2217\/cer-2020-0092","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T08:49:51Z","timestamp":1596012591000},"page":"891-902","source":"Crossref","is-referenced-by-count":8,"title":["Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany"],"prefix":"10.57264","volume":"9","author":[{"given":"Klaus","family":"Krueger","sequence":"first","affiliation":[{"name":"Rheumatologisches Praxiszentrum, St. Bonifatius Str. 5, Munich, 81541, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Remstedt","sequence":"additional","affiliation":[{"name":"Rheuma Praxis, Elsenstr. 111, Berlin, 12435, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Thiele","sequence":"additional","affiliation":[{"name":"Krankenhaus St. Josef, Bergstr. 6-12, Wuppertal, 42105, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9194-9347","authenticated-orcid":false,"given":"Susanne","family":"Hohenberger","sequence":"additional","affiliation":[{"name":"Medical Affairs, MSD Sharp &amp; Dohme GmbH, Lindenplatz 1, Haar, 85540, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_8_2_2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1478-6354-13-S1-S4","article-title":"Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future","volume":"13","author":"Schett G","year":"2011","unstructured":"Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res. Ther. 13(Suppl. 1), S4 (2011).","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3899\/jrheum.150540","article-title":"Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort","volume":"43","author":"Greenberg JD","year":"2016","unstructured":"Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare resource use and direct costs in patients with ankylosing spondylitis and psoriatic arthritis in a large US cohort. J. Rheumatol. 43(1), 88\u201396 (2016).","journal-title":"J. Rheumatol."},{"issue":"6","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/1756-185X.13526","article-title":"Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort","volume":"22","author":"Claudepierre P","year":"2019","unstructured":"Claudepierre P, van den Bosch F, Sarzi-Puttini P, Vastesaeger N, Govoni M, Kachroo S. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. Int. J. Rheum. Dis. 22(6), 995\u20131001 (2019).","journal-title":"Int. J. Rheum. Dis."},{"issue":"2","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3899\/jrheum.090242","article-title":"Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis","volume":"37","author":"Maksymowych WP","year":"2010","unstructured":"Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J. Rheumatol. 37(2), 385\u2013392 (2010).","journal-title":"J. Rheumatol."},{"issue":"3","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s12325-018-0866-y","article-title":"Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis","volume":"36","author":"Nakagawa H","year":"2019","unstructured":"Nakagawa H, Tanaka Y, Sano S Real-world postmarketing study of the impact of adalimumab treatment on work productivity and activity impairment in patients with psoriatic arthritis. Adv. Ther. 36(3), 691\u2013707 (2019).","journal-title":"Adv. Ther."},{"issue":"3","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12325-017-0477-z","article-title":"Impact of adalimumab on work productivity and activity impairment in japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study","volume":"34","author":"Takeuchi T","year":"2017","unstructured":"Takeuchi T, Nakajima R, Komatsu S Impact of adalimumab on work productivity and activity impairment in japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study. Adv. Ther. 34(3), 686\u2013702 (2017).","journal-title":"Adv. Ther."},{"issue":"2","key":"e_1_3_8_8_2","first-page":"598","article-title":"FRI0108 Golimumab improves work productivity and activity and quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PSA) and axial spondyloarthritis (AXSPA): interim results from a non-interventional study in austria (go active)","volume":"77","author":"Dejaco C","year":"2018","unstructured":"Dejaco C, Mueller T, Zamani O FRI0108 Golimumab improves work productivity and activity and quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PSA) and axial spondyloarthritis (AXSPA): interim results from a non-interventional study in austria (go active). Ann. Rheumatic Dis. 77(Suppl. 2), 598\u2013599 (2018).","journal-title":"Ann. Rheumatic Dis."},{"issue":"6","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study","volume":"68","author":"Keystone EC","year":"2009","unstructured":"Keystone EC, Genovese MC, Klareskog L Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann. Rheum. Dis. 68(6), 789\u2013796 (2009).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh A","year":"2009","unstructured":"Kavanaugh A, Mcinnes I, Mease P Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60(4), 976\u2013986 (2009).","journal-title":"Arthritis Rheum."},{"issue":"11","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial","volume":"58","author":"Inman RD","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde D Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum. 58(11), 3402\u20133412 (2008).","journal-title":"Arthritis Rheum."},{"issue":"1","key":"e_1_3_8_12_2","first-page":"107","article-title":"An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab","volume":"38","author":"Scrivo R","year":"2020","unstructured":"Scrivo R, Giardino AM, Salvarani C An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. Clin. Exp. Rheumatol. 38(1), 107\u2013114 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"e021082","DOI":"10.1136\/bmjopen-2017-021082","article-title":"Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany","volume":"8","author":"Kruger K","year":"2018","unstructured":"Kruger K, Burmester GR, Wassenberg S, Bohl-Buhler M, Thomas MH. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 8(6), e021082 (2018).","journal-title":"BMJ Open"},{"issue":"7","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.socscimed.2004.08.034","article-title":"A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis","volume":"60","author":"Marra CA","year":"2005","unstructured":"Marra CA, Woolcott JC, Kopec JA A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60(7), 1571\u20131582 (2005).","journal-title":"Soc. Sci. Med."},{"issue":"6","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/art.22887","article-title":"Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study","volume":"57","author":"Davis JC","year":"2007","unstructured":"Davis JC Jr, Revicki D, van der Heijde DM Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum. 57(6), 1050\u20131057 (2007).","journal-title":"Arthritis Rheum."},{"issue":"10","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/acr.22022","article-title":"Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States","volume":"65","author":"Hone D","year":"2013","unstructured":"Hone D, Cheng A, Watson C Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States. Arthritis Care Res. (Hoboken) 65(10), 1564\u20131572 (2013).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"2","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jaad.2010.10.020","article-title":"The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis","volume":"66","author":"Kimball AB","year":"2012","unstructured":"Kimball AB, Yu AP, Signorovitch J The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J. Am. Acad. Dermatol. 66(2), e67\u2013e76 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"e0200758","DOI":"10.1371\/journal.pone.0200758","article-title":"Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: a 1-year mirror-image study using a national claims database","volume":"13","author":"Chen KC","year":"2018","unstructured":"Chen KC, Wu CH, Tang CH, Huang KC. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: a 1-year mirror-image study using a national claims database. PLoS ONE 13(7), e0200758 (2018).","journal-title":"PLoS ONE"},{"issue":"6","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10198-011-0335-x","article-title":"Cost\u2013effectiveness of golimumab for the treatment of active psoriatic arthritis","volume":"13","author":"Cummins E","year":"2012","unstructured":"Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS. Cost\u2013effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur. J. Health Econ. 13(6), 801\u2013809 (2012).","journal-title":"Eur. J. Health Econ."},{"issue":"2","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40744-017-0083-1","article-title":"Cost\u2013effectiveness of golimumab in ankylosing spondylitis from the UK payer perspective","volume":"4","author":"Borse RH","year":"2017","unstructured":"Borse RH, Brown C, Muszbek N, Chaudhary MA, Kachroo S. Cost\u2013effectiveness of golimumab in ankylosing spondylitis from the UK payer perspective. Rheumatol. Ther. 4(2), 427\u2013443 (2017).","journal-title":"Rheumatol. Ther."},{"issue":"5","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"e027456","DOI":"10.1136\/bmjopen-2018-027456","article-title":"Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review","volume":"9","author":"Luttropp K","year":"2019","unstructured":"Luttropp K, Dozier M, Justo N Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review. BMJ Open 9(5), e027456 (2019).","journal-title":"BMJ Open"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T23:44:21Z","timestamp":1723333461000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.2217\/cer-2020-0092"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0092","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}